Cited by

• Pharmacokinetic considerations in the treatment of tuberculosis in patients with renal failure.

  Launay-Vacher V, Izzedine H, Deray G. Launay-Vacher V, et al. Clin Pharmacokinet. 2005;44(3):221-35. doi: 10.2165/00003088-200544030-00001. Clin Pharmacokinet. 2005. PMID: 15762766 Review.
• Pharmacokinetics of imipenem-cilastatin in critically ill patients undergoing continuous venovenous hemofiltration.

  Tegeder I, Bremer F, Oelkers R, Schobel H, Schüttler J, Brune K, Geisslinger G. Tegeder I, et al. Antimicrob Agents Chemother. 1997 Dec;41(12):2640-5. doi: 10.1128/AAC.41.12.2640. Antimicrob Agents Chemother. 1997. PMID: 9420033 Free PMC article.
• Programmed Necrosis and Disease:We interrupt your regular programming to bring you necroinflammation.

  Kim EH, Wong SW, Martinez J. Kim EH, et al. Cell Death Differ. 2019 Jan;26(1):25-40. doi: 10.1038/s41418-018-0179-3. Epub 2018 Oct 22. Cell Death Differ. 2019. PMID: 30349078 Free PMC article. Review.
• The clinical relevance of necroinflammation-highlighting the importance of acute kidney injury and the adrenal glands.

  Tonnus W, Gembardt F, Latk M, Parmentier S, Hugo C, Bornstein SR, Linkermann A. Tonnus W, et al. Cell Death Differ. 2019 Jan;26(1):68-82. doi: 10.1038/s41418-018-0193-5. Epub 2018 Sep 17. Cell Death Differ. 2019. PMID: 30224638 Free PMC article. Review.
• Use of etoposide in patients with organ dysfunction: pharmacokinetic and pharmacodynamic considerations.

  Stewart CF. Stewart CF. Cancer Chemother Pharmacol. 1994;34 Suppl:S76-83. doi: 10.1007/BF00684868. Cancer Chemother Pharmacol. 1994. PMID: 8070032 Review.